LIQUIDIA CORPORATION INVESTIGATION: LQDA Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

Kirby McInerney LLP announced an investigation into potential securities-law claims against Liquidia Corporation following a court ruling involving its lead product Yutrepia. On September 30, 2026, the U.S. District Court for the District of Delaware found Yutrepia infringed claims 1 and 14 of United Therapeutics' '327 patent covering pulmonary hypertension with interstitial lung disease. Liquidia shares fell approximately 57.2%, from $70.69 to $30.26, on the ruling; CEO Roger Jeffs said the company would pursue all available appellate options.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.